Standard Biotools Inc. (LAB): Gross Profit
$42.54M
Year ended 2025-12-31
$42.71M
Trailing 12 months to 2026-06-30
+4.7%
3-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.54M | -5.2% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $44.88M | -11.0% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $50.45M | +36.2% | 2026-03-16, From 2023-01-01 |
| 2022-12-31 | $37.05M | n/a | 2025-03-11, From 2022-01-01 |
| No annual figure between 2019-12-31 and 2022-12-31. | |||
| 2019-12-31 | $64.28M | +4.3% | 2020-02-27, From 2019-01-01 |
| 2018-12-31 | $61.65M | +18.6% | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | $51.98M | -11.0% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $58.44M | n/a | 2019-03-18, From 2016-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.54M | -5.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $75.56M | +16.4% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $42.74M | +82.6% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $64.87M | -39.6% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $11.70M | -33.1% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $97.34M | +19.4% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $42.34M | +15.1% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $795.0K | n/a |
| Gyre Therapeutics, Inc. (GYRE) | 2024-12-31 | $101.87M | -6.4% |
Compare LAB, ADCT, ETON, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗